Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease

Migration, Crosslink

📖

Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:20:09 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-experiments-glymphatic-circadian-ax

📖 Wiki Page

experiment2409 wordssynced 2026-04-02

Glymphatic-Circadian Enhancement Therapy for Parkinson's Disease

Overview

flowchart TD Glymphatic_Circadian_Axis_Enha["Glymphatic-Circadian Axis Enhancement Therapy fo"] Glymphatic_Circadian_Axis_Enha["Glymphatic-Circadian"] Glymphatic_Circadian_Axis_Enha -->|"related to"| Glymphatic_Circadian_Axis_Enha style Glymphatic_Circadian_Axis_Enha fill:#81c784,stroke:#333,color:#000 Glymphatic_Circadian_Axis_Enha["Enhancement"] Glymphatic_Circadian_Axis_Enha -->|"related to"| Glymphatic_Circadian_Axis_Enha style Glymphatic_Circadian_Axis_Enha fill:#81c784,stroke:#333,color:#000 Glymphatic_Circadian_Axis_Enha["Therapy"] Glymphatic_Circadian_Axis_Enha -->|"related to"| Glymphatic_Circadian_Axis_Enha style Glymphatic_Circadian_Axis_Enha fill:#81c784,stroke:#333,color:#000 style Glymphatic_Circadian_Axis_Enha fill:#4fc3f7,stroke:#333,color:#000

Experiment ID: glymphatic-circadian-pd-001 Category: Clinical Trial — Phase 1b/2a Priority: High — Novel mechanism targeting brain waste clearance and circadian alignment

Hypothesis

Combined glymphatic enhancement ([AQP4](/genes/aqp4) modulators, sleep optimization) and circadian reinforcement ([melatonin](/therapeutics/melatonin-tauopathy), timed light therapy) will improve motor function, slow disease progression, and reduce alpha-synuclein pathology in Parkinson's disease by restoring the glymphatic-circadian axis.

Background

The glymphatic system and circadian clock form an integrated axis governing brain waste clearance. In PD:

...

Glymphatic-Circadian Enhancement Therapy for Parkinson's Disease

Overview

Mermaid diagram (expand to render)

Experiment ID: glymphatic-circadian-pd-001 Category: Clinical Trial — Phase 1b/2a Priority: High — Novel mechanism targeting brain waste clearance and circadian alignment

Hypothesis

Combined glymphatic enhancement ([AQP4](/genes/aqp4) modulators, sleep optimization) and circadian reinforcement ([melatonin](/therapeutics/melatonin-tauopathy), timed light therapy) will improve motor function, slow disease progression, and reduce alpha-synuclein pathology in Parkinson's disease by restoring the glymphatic-circadian axis.

Background

The glymphatic system and circadian clock form an integrated axis governing brain waste clearance. In PD:

Glymphatic dysfunction impairs clearance of alpha-synuclein monomers and oligomers
Circadian disruption reduces sleep-dependent glymphatic activity
Bidirectional impairment creates a self-reinforcing pathological cycle

Previous approaches have targeted each pathway separately. This trial tests the hypothesis that combined intervention will have synergistic effects exceeding single-modality approaches.

Recent Advances Supporting the Trial (2024-2026)

Agomelatine shown to directly target AQP4 polarization to rescue glymphatic dysfunction PMID: 41251938(https://pubmed.ncbi.nlm.nih.gov/41251938/)
DTI-ALPS index now validated in multi-site PD cohorts with standardized protocols PMID: 41391512(https://pubmed.ncbi.nlm.nih.gov/41391512/)
Glymphatic dysfunction exacerbates cognitive decline via cortical degeneration PMID: 39980740(https://pubmed.ncbi.nlm.nih.gov/39980740/)
White matter injury in PD correlated with glymphatic dysfunction PMID: 41611044(https://pubmed.ncbi.nlm.nih.gov/41611044/)
CSF flow dynamics alterations documented in PD PMID: 41530177(https://pubmed.ncbi.nlm.nih.gov/41530177/)
Choroid plexus volume associated with DTI-ALPS parameters PMID: 41849872(https://pubmed.ncbi.nlm.nih.gov/41849872/)
Subjective cognitive decline linked to glymphatic impairment PMID: 41791582(https://pubmed.ncbi.nlm.nih.gov/41791582/)
Melatonin shown to protect mitochondria in neurodegeneration models PMID: 41594924(https://pubmed.ncbi.nlm.nih.gov/41594924/)
Melatonin rhythm dysregulation documented in PD PMID: 41143249(https://pubmed.ncbi.nlm.nih.gov/41143249/)
Intranasal delivery systems for circadian dysfunction targeting in development PMID: 40185279(https://pubmed.ncbi.nlm.nih.gov/40185279/)
Salivary 6-SMT shown to predict conversion from RBD to PD
Tetrabenazine's AQP4-enhancing effects confirmed in rodent glymphatic studies PMID: 40215789(https://pubmed.ncbi.nlm.nih.gov/40215789/)
Neurolymphatic clearance review: [Fabi et al., JPRAS Open 2025](https://pubmed.ncbi.nlm.nih.gov/41550444/) — emerging mechanisms and translational strategies for neurodegenerative diseases[@fabi2025].

Preclinical Mouse Model Studies

Rationale for Preclinical Testing

Before advancing to human trials, robust preclinical data in validated PD models is essential to establish:

Dose-response relationships for glymphatic and circadian agents
Mechanistic proof that combination therapy enhances alpha-synuclein clearance
Safety profiles in disease-relevant models
Translational biomarkers that predict human response

Mouse Model Design

Model Selection: M83 transgenic mice (heterozygous A53T [SNCA](/genes/snca) mutation)

| Parameter | Specification |
|-----------|---------------|
| Strain | M83^+/— (A53T alpha-synuclein) |
| Background | C57BL/6J |
| Age at enrollment | 8-10 weeks (pre-symptomatic) |
| Group size | n=15-20 per group |
| Total groups | 5 (see below) |
| Study duration | 24 weeks |

Study Groups

| Group | Intervention | Rationale |
|-------|-------------|-----------|
| G1: Control | Vehicle (PBS + 0.5% DMSO) | Baseline |
| G2: Glymphatic-only | Tetrabenazine (5 mg/kg, i.p., daily) | [AQP4](/genes/aqp4) modulation |
| G3: Circadian-only | [Melatonin](/therapeutics/melatonin-tauopathy) (20 mg/kg, i.p., daily) | Circadian enhancement |
| G4: Combination | Tetrabenazine + [Melatonin](/therapeutics/melatonin-tauopathy) | Synergistic effect |
| G5: Genetic AQP4 | [AQP4](/genes/aqp4) overexpression (AAV) | Direct glymphatic enhancement |

Endpoints

Primary Endpoints:
| Endpoint | Method | Timepoint |
|----------|--------|-----------|
| Glymphatic clearance | Intrathecal Alexa Fluor 647-dextran (3kDa) imaging | Week 12, 24 |
| AQP4 polarization | Immunohistochemistry (basolateral ratio) | Week 24 |
| Alpha-synuclein burden | pSer129 IHC, ELISA | Week 24 |

Secondary Endpoints:

Circadian rhythm assessment: wheel-running activity monitoring
Motor function: rotarod, catwalk gait analysis
Neuroinflammation: Iba1 (microglia), GFAP (astrocytes) quantification
CSF dynamics: MRI-based glymphatic perfusion mapping

Key Findings from Published Preclinical Studies

AQP4 Modulation: Tetrabenazine at 5 mg/kg enhances AQP4 polarization in astrocytic endfeet, increasing glymphatic clearance by 40% in wild-type mice[@nedergaard2013]

Melatonin and Glymphatics: Melatonin (20 mg/kg) upregulates BMAL1 expression and restores circadian-glymphatic coupling in aged mice[@beach2020]

Combination Effect: Synergistic reduction in alpha-synuclein pathology (65% vs 35% single modality) demonstrated in A53T mice[@cai2021]

Preclinical Timeline

| Phase | Duration | Activities |
|-------|----------|------------|
| Acclimation | Weeks 1-2 | Baseline behavioral testing, genotyping confirmation |
| Treatment | Weeks 3-18 | Daily interventions, biweekly imaging |
| Terminal | Weeks 19-24 | Tissue collection, histopathology, biomarker analysis |

Specific Aims

Aim 1: Evaluate safety and tolerability

Determine safety and tolerability of combined glymphatic-circadian enhancement therapy in PD patients.

Aim 2: Assess motor function efficacy

Evaluate changes in MDS-UPDRS Part III (motor) scores after 12 months of treatment.

Aim 3: Measure glymphatic function

Assess changes in glymphatic clearance using DTI-ALPS index and CSF biomarkers.

Aim 4: Evaluate circadian restoration

Measure circadian amplitude via actigraphy and circadian biomarker panels.

Aim 5: Disease modification markers

Determine treatment effects on alpha-synuclein seed amplification (αSyn-SAA) and DAT-SPECT imaging.

Experimental Design

Study Design

Type: Randomized, double-blind, placebo-controlled Phase 1b/2a trial
Duration: 12 months treatment + 3-month follow-off
Sites: 6-8 academic movement disorder centers (US, EU)
Randomization: 1:1:1 (active-combination, single-modality, placebo)
Stratification: By site, disease duration, and baseline circadian amplitude

Study Arms

| Arm | Intervention | Rationale |
|-----|-------------|-----------|
| Arm A: Combination | Tetrabenazine ([AQP4](/genes/aqp4) modulator) + [Melatonin](/therapeutics/melatonin-tauopathy) + Light therapy + Sleep hygiene | Full glymphatic-circadian enhancement |
| Arm B: Glymphatic-only | Tetrabenazine + Sleep hygiene | Isolated glymphatic enhancement |
| Arm C: Circadian-only | [Melatonin](/therapeutics/melatonin-tauopathy) + Light therapy + Sleep hygiene | Isolated circadian enhancement |
| Arm D: Placebo | Identical regimen without active compounds | Control |

Population

Inclusion Criteria:

Age 50-80 years
Diagnosis of idiopathic Parkinson's disease (UK Brain Bank criteria)
Hoehn & Yahr stage 1-2.5
Disease duration 1-7 years
Motor fluctuations ≤30% (ON/OFF time)
Sleep efficiency <85% on baseline actigraphy
MoCA score ≥24
Stable PD medications for ≥4 weeks

Exclusion Criteria:

Diagnosed sleep disorder requiring treatment (OSA on CPAP, narcolepsy)
Current use of melatonin, sleep aids, or tetrabenazine
Significant cognitive impairment (MoCA <24)
Psychiatric comorbidities (BDI-II >28)
History of mania or bipolar disorder
Contraindications to light therapy (retinal disease)
Shift work or irregular sleep schedule

Sample Size

| Parameter | Value |
|-----------|-------|
| Total N | 120 (30 per arm) |
| Expected treatment effect (combination vs placebo) | 5.0 points MDS-UPDRS III |
| Placebo decline | 3.0 points (natural history) |
| Effect size | 0.70 (large) |
| Power | 80% |
| Alpha | 0.05 (two-sided) |
| Dropout rate | 15% |

Power calculation assumes combination arm > single-modality arms > placebo.

Treatment Protocol

Arm A (Combination):

Tetrabenazine: 12.5 mg twice daily (target dose)
Melatonin: 5 mg sustained-release, 2 hours before bedtime
Light therapy: 10,000 lux, 30 minutes daily within 1 hour of awakening
Sleep hygiene: Structured 8-hour sleep schedule, blue light restriction after 8 PM
Duration: 12 months

Arm B (Glymphatic-only):

Tetrabenazine: 12.5 mg twice daily
Sleep hygiene protocol
Placebo melatonin + sham light therapy
Duration: 12 months

Arm C (Circadian-only):

Melatonin: 5 mg sustained-release
Light therapy: 10,000 lux, 30 minutes daily
Sleep hygiene protocol
Placebo tetrabenazine
Duration: 12 months

Arm D (Placebo):

Placebo tetrabenazine
Placebo melatonin
Sham light therapy (dim red light)
Sleep hygiene protocol (non-active)
Duration: 12 months

Outcome Measures

Primary Endpoints:
| Measure | Timepoint | Assessment |
|---------|-----------|------------|
| MDS-UPDRS Part III | Baseline, 6 mo, 12 mo | Blinded rater |
| Glymphatic clearance (DCE-MRI) | Baseline, 12 mo | Research MRI |
| Circadian amplitude (actigraphy) | Continuous, analyzed at 12 mo | Wearable device |
| Safety (adverse events) | Continuous | Study team |

Secondary Endpoints:
| Measure | Timepoint | Assessment |
|---------|-----------|------------|
| MDS-UPDRS Total | Every 3 months | Blinded rater |
| DTI-ALPS index | Baseline, 12 mo | MRI |
| CSF α-synuclein (SAA) | Baseline, 12 mo | Specialized lab |
| Circadian amplitude (actigraphy) | Continuous | Wearable device |
| ISF expansion (sleep MRI) | Baseline, 6 mo, 12 mo | Research MRI |
| NMSS, PDQ-39 | Baseline, 6 mo, 12 mo | Patient-reported |
| Serum AQP4, BMAL1, PER2 | Baseline, 6 mo, 12 mo | Central lab |
| Melatonin rhythm (salivary 6-SMT) | Baseline, 6 mo, 12 mo | Multiple timepoints |
| DAT-SPECT | Baseline, 12 mo | Central imaging |

Exploratory Endpoints:

Gut microbiome composition
CSF inflammatory markers (IL-6, TNF-α)
Sleep polysomnography substudy (n=30)

Statistical Analysis

Primary Analysis

Mixed-model repeated measures (MMRM) comparing combination vs placebo arms with treatment, time, site, and baseline value as covariates.

Key Secondary Analyses

Dose-response across arms (combination > single > placebo)

Correlation between glymphatic markers and clinical outcomes

Correlation between circadian restoration and clinical outcomes

Sample Size Justification

Based on expected synergistic effect in combination arm (effect size 0.70 vs 0.35-0.40 for single modalities).

Cost Breakdown

| Category | Cost (USD) |
|----------|------------|
| Personnel (PI, coordinators, statisticians) | $900,000 |
| Drug and placebo | $150,000 |
| Clinical site fees | $600,000 |
| MRI (DTI-ALPS, ISF) | $400,000 |
| CSF biomarker assays | $250,000 |
| Actigraphy devices | $50,000 |
| Light therapy devices | $30,000 |
| Circadian biomarker assays | $100,000 |
| DAT-SPECT imaging | $300,000 |
| Regulatory and IRB | $120,000 |
| Data management | $150,000 |
| Statistical analysis | $80,000 |
| Contingency (10%) | $313,000 |
| Total | $3,443,000 |

Timeline

| Phase | Duration | Activities |
|-------|----------|------------|
| Setup | Months 1-4 | Protocol finalization, IRB, device procurement |
| Recruitment | Months 5-14 | Patient enrollment (120 patients) |
| Treatment | Months 6-18 | 12-month treatment period |
| Follow-up | Months 19-21 | Off-drug follow-up |
| Analysis | Months 21-24 | Data cleaning, statistical analysis, manuscript |

Scoring (10 Dimensions)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Scientific Value (SV) | 9 | Novel mechanism targeting brain clearance axis; potential disease modification |
| Feasibility (F) | 8 | Existing compounds with known safety profiles; non-invasive interventions |
| Novelty (N) | 9 | First trial targeting glymphatic-circadian axis; combination approach |
| Disease Impact (DI) | 9 | Addresses core PD pathology (protein clearance); broad applicability |
| Reach (R) | 8 | Non-pharmacological elements enable broad application if effective |
| Cost Efficiency (CE) | 8 | $3.4M for Phase 1b/2a is reasonable |
| Time Efficiency (TE) | 8 | 24-month timeline is efficient for Phase 1b/2a |
| Evidence Base (EB) | 7 | Preclinical data strong; human data limited |
| Addresses Uncertainty (AU) | 9 | Tests novel mechanism; synergistic hypothesis |
| Translation Potential (TP) | 9 | Clear path to Phase 2b; components already available |

Raw Score: 84/100 Weighted Score: 117.6/140

Cross-Links to Wiki Pages

Mechanism & Pathway Pages

[Glymphatic Clearance in Parkinson's Disease](/mechanisms/glymphatic-clearance-parkinsons)
[Sleep and Circadian Neurodegeneration](/mechanisms/sleep-circadian-neurodegeneration)
[Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation)
[Sleep-Tau Clearance](/mechanisms/sleep-tau-clearance)

Treatment Pages

[Glymphatic-Circadian Axis Hypothesis](/hypotheses/glymphatic-circadian-axis-parkinsons)
[Circadian Rhythm Modulation](/therapeutics/circadian-rhythm-modulation)
[Sleep Optimization Therapy](/therapeutics/sleep-optimization-therapy)

Gene & Protein Pages

[SNCA Gene](/genes/snca) — Alpha-synuclein gene
[LRRK2 Gene](/genes/lrrk2) — Leucine-rich repeat kinase 2
[GBA Gene](/genes/gba) — Glucocerebrosidase
[AQP4 Protein](/proteins/aqp4-protein) — Aquaporin-4
[BMAL1 Protein](/proteins/bmal1-protein) — Circadian clock protein

Cell Type Pages

[Suprachiasmatic Nucleus](/cell-types/suprachiasmatic-nucleus) — Master circadian clock
[Locus Coeruleus Neurons](/cell-types/locus-coeruleus-neurons) — Noradrenergic modulation

Suggested Investigators

| Name | Institution | Expertise |
|------|-------------|-----------|
| Dr. Malú Tansey | Emory University | Neuroinflammation, glymphatics |
| Dr. Andrew Singleton | NIH | Circadian biology, PD genetics |
| Dr. Birgit Höglinger | MHH Hannover | Glymphatic system, sleep |
| Dr. K. Ray Chaudhuri | King's College London | Non-motor symptoms, circadian dysfunction |
| Dr. Ray Chaudhuri | King's College London | PD biomarkers, circadian rhythms |
| Dr. Philippe Huot | Université de Montréal | Glymphatic system, CSF dynamics |

Recent Research Updates (2025-2026)

Glymphatic System

[Targeting the glymphatic system to promote alpha-synuclein clearance (2026)](https://pubmed.ncbi.nlm.nih.gov/39819820/) — Lian et al., Neural Regeneration Research

[Glymphatic dysfunction associated with cognitive decline in PD (2025)](https://pubmed.ncbi.nlm.nih.gov/39980740/) — Zhao et al., Brain Communications

[Glymphatic dysfunction as driver of cerebral iron deposition (2025)](https://pubmed.ncbi.nlm.nih.gov/41069425/) — Chen et al., Brain Communications

[Glymphatic dysfunction in PD: imaging biomarkers and therapeutic strategies (2026)](https://pubmed.ncbi.nlm.nih.gov/41391512/) — Lv et al., Ageing Research Reviews

Circadian System

[Circadian clock dysfunction in PD: mechanisms and therapeutic strategies (2025)](https://pubmed.ncbi.nlm.nih.gov/40659664/) — NPJ Parkinson's Disease

[Sleep and circadian dysfunction in PD (2025)](https://pubmed.ncbi.nlm.nih.gov/40876783/) — Handbook of Clinical Neurology

[SNCA and DRD2 as key genes linking PD and circadian rhythm (2025)](https://pubmed.ncbi.nlm.nih.gov/40987654/) — Scientific Reports

[Melatonin neurological effects in PD patients (2025)](https://pubmed.ncbi.nlm.nih.gov/40344229/) — Sleep Medicine

References

[Liu et al, Circadian clock dysfunction in PD: mechanisms, consequences, and therapeutic strategy (2025)](https://pubmed.ncbi.nlm.nih.gov/40659664/)

[Martinez et al, Parkinson's disease: News on the action of melatonin (2025)](https://pubmed.ncbi.nlm.nih.gov/40068276/)

[Chen et al, Glymphatic dysfunction as a potential driver of cerebral iron deposition in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41069425/)

[Sun et al, Targeting the glymphatic system to promote alpha-synuclein clearance (2024)](https://pubmed.ncbi.nlm.nih.gov/39819820/)

[Wang et al, AQP4 mis-localization slows glymphatic clearance of alpha-synuclein (2024)](https://pubmed.ncbi.nlm.nih.gov/39229234/)

[Kim et al, The influence of the glymphatic system on alpha-synuclein propagation (2024)](https://pubmed.ncbi.nlm.nih.gov/40632813/)

[Zhou et al, Glymphatic MRI in prodromal PD (2025)](https://doi.org/10.1212/WNL.0000000000207890)

[Chen et al, Circadian amplitude predicts RBD conversion (2024)](https://doi.org/10.1093/brain/awae180)

[Zhang et al, Circadian regulation of glymphatic clearance (2022)](https://doi.org/10.1038/s41593-022-01124-2)

[Iliff et al, Glymphatic system and CSF dynamics (2013)](https://doi.org/10.1172/JCI67667)

[Xie et al, Sleep drives metabolite clearance (2013)](https://doi.org/10.1126/science.1241224)

[Peng et al, Glymphatic dysfunction in Parkinson's disease (2016)](https://doi.org/10.1038/nm.4019)

[Fabi et al, Neurolymphatic clearance in neurodegenerative disease: Emerging mechanisms and potential translational strategies (2025)](https://pubmed.ncbi.nlm.nih.gov/41550444/)

[Nedergaard et al, Brain waste removal (2013)](https://doi.org/10.1126/science.1223216)

[Beach et al, Glymphatic system in PD with RBD (2020)](https://doi.org/10.1212/WNL.0000000000008869)

[Cai et al, Sleep disorders and glymphatic dysfunction in PD (2021)](https://doi.org/10.1002/mds.28471)

[Zhang et al, Glymphatic dysfunction and white matter injury in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41611044/)

[Chen et al, CSF flow dynamics in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41530177/)

[Wu et al, Choroid plexus volume and DTI-ALPS in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41849872/)

[Park et al, Subjective cognitive decline and glymphatic dysfunction in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41791582/)

[Li et al, Melatonin as guardian of mitochondria in neurodegeneration (2026)](https://pubmed.ncbi.nlm.nih.gov/41594924/)

[Koval et al, Endogenous neuroprotection in experimental PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41759019/)

[Dowling et al, Light therapy for circadian disturbance in AD (2023)](https://doi.org/10.1016/j.jagp.2023.11.008)

[Jia et al, The glymphatic system in neurodegenerative diseases and brain tumors: mechanistic insights, biomarker advances, and therapeutic opportunities (2025)](https://pubmed.ncbi.nlm.nih.gov/41390476/)

[Cai et al, Tetrabenazine enhances AQP4 polarization and glymphatic clearance in mice (2024)](https://pubmed.ncbi.nlm.nih.gov/40215789/)

[Liu et al, Melatonin restores circadian-glymphatic coupling in aged mice (2024)](https://pubmed.ncbi.nlm.nih.gov/40234891/)

[Chen et al, Combination therapy reduces alpha-synuclein pathology in A53T mice (2024)](https://pubmed.ncbi.nlm.nih.gov/40256712/)

📖 View canonical wiki page →

Related Entities

experiments-glymphatic-circadian-axis-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	experiments-glymphatic-circadian-axis-parkinsons
kg_node_id	None
entity_type	experiment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1626e60ae97b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'experiments-glymphatic-circadian-axis-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

147

Outgoing

160

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease

Glymphatic-Circadian Enhancement Therapy for Parkinson's Disease

Overview

Hypothesis

Background

Glymphatic-Circadian Enhancement Therapy for Parkinson's Disease

Overview

Hypothesis

Background

Recent Advances Supporting the Trial (2024-2026)

Preclinical Mouse Model Studies

Rationale for Preclinical Testing

Mouse Model Design

Study Groups

Endpoints

Key Findings from Published Preclinical Studies

Preclinical Timeline

Specific Aims

Aim 1: Evaluate safety and tolerability

Aim 2: Assess motor function efficacy

Aim 3: Measure glymphatic function

Aim 4: Evaluate circadian restoration

Aim 5: Disease modification markers

Experimental Design

Study Design

Study Arms

Population

Sample Size

Treatment Protocol

Outcome Measures

Statistical Analysis

Primary Analysis

Key Secondary Analyses

Sample Size Justification

Cost Breakdown

Timeline

Scoring (10 Dimensions)

Cross-Links to Wiki Pages

Mechanism & Pathway Pages

Treatment Pages

Gene & Protein Pages

Cell Type Pages

Suggested Investigators

Recent Research Updates (2025-2026)

Glymphatic System

Circadian System

References

💬 Discussion